Cover Image
Market Research Report

Global Active Pharmaceutical Ingredients Market Forecast 2019-2027

Published by Inkwood Research Product code 819216
Published Content info 153 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global Active Pharmaceutical Ingredients Market Forecast 2019-2027
Published: April 8, 2019 Content info: 153 Pages
Description

KEY FINDINGS

There are various chemicals that are contained within the drugs and the portion that catalyzes in treating the condition, i.e., the active part is known as the 'active pharmaceutical ingredients' or API. The growing rate of geriatric population and the subsequent rising incidences of age-related diseases are driving the demand of the active pharmaceutical ingredients in the market.

The global active pharmaceutical ingredients (APIs) market is anticipated to generate revenue of $XX billion by 2027 and is expected to proliferate at a CAGR of 6.10% through the forecasting years of 2019-2027.

MARKET INSIGHTS

As mentioned earlier, the growing demand for drugs to treat the aging population will primarily boost market growth during the forecast period. The applications of active pharmaceutical ingredients and APIs synthesis market are very versatile. The cardiovascular disease, oncology, CNS and neurological disorders, orthopedic disorders, endocrinology, pulmonology, gastrointestinal disorders, nephrology, ophthalmology, and other application employ the APIs for their respective treatment.

The high amount of investment and production cost and aggressive competition among API manufacturers are the major factors hindering the active pharmaceutical ingredients market. API manufacture requires sophisticated infrastructure, and thus it is capital intensive. API giants are employing strategies to distinguish themselves, which is further escalating the competition in the market.

REGIONAL INSIGHTS

The global active pharmaceutical ingredients market has been segmented on the basis of four major geographical regions, namely, North America, Asia Pacific, Europe, and the remaining countries collectively forming the Rest of World regional segment.

The active pharmaceutical ingredients market in North America is projected to capture the largest market share by 2027 due to the higher demand for generic drugs, especially from the United States. Patent expiries of blockbuster drugs are also expected to contribute to market growth.

COMPETITIVE INSIGHTS

Sun Pharmaceuticals Industries, Ltd., Abbvie, Inc., Novartis, Eli Lilly and Company, Lonza Group AG, Merck & Co., Inc., Mylan N.V., Boehringer Ingelheim GmbH, Aurobindo Pharma, Teva Pharmaceutical Industries, Ltd., Bayer AG, Bristol-Myers Squibb, Albemarle Corporation, Cipla, and Dr. Reddy's Laboratories are the major companies operating in the region which have been profiled in the report.

Table of Contents
Product Code: 24578

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
    • 3.2.2. MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
    • 3.2.3. BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
    • 3.2.4. ONCOLOGY IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWING GERIATRIC POPULATION
    • 4.2.2. GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
    • 4.2.3. INCREASING INCIDENCE OF AGE-RELATED DISEASES
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HIGH COST OF INVESTMENT AND PRODUCTION COST
    • 4.3.2. AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. GAINING POPULARITY FOR TARGETED THERAPY
    • 4.4.2. GROWING PREFERENCE FOR OUTSOURCING APIS
    • 4.4.3. IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
  • 4.5. MARKET CHALLENGES
    • 4.5.1. STRINGENT GOVERNMENT REGULATIONS
    • 4.5.2. AVAILABILITY OF COUNTERFEIT PRODUCTS

5. MARKET BY TYPES

  • 5.1. GENERIC APIS
  • 5.2. INNOVATIVE APIS

6. MARKET BY MANUFACTURERS

  • 6.1. CAPTIVE APIS
  • 6.2. MERCHANT APIS

7. MARKET BY SYNTHESIS

  • 7.1. BIOTECH
    • 7.1.1. MONOCLONAL ANTIBODIES
    • 7.1.2. RECOMBINANT PROTEINS
    • 7.1.3. VACCINES
  • 7.2. SYNTHETIC

8. MARKET BY APPLICATION

  • 8.1. CARDIOVASCULAR DISEASE
  • 8.2. ONCOLOGY
  • 8.3. CNS AND NEUROLOGICAL DISORDERS
  • 8.4. ORTHOPEDIC DISORDERS
  • 8.5. ENDOCRINOLOGY
  • 8.6. PULMONOLOGY
  • 8.7. GASTROINTESTINAL DISORDERS
  • 8.8. NEPHROLOGY
  • 8.9. OPHTHALMOLOGY
  • 8.10. OTHER APPLICATION

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREAT OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
    • 9.1.5. THREAT OF COMPETITIVE RIVALRY
  • 9.2. SALES ANALYSIS
  • 9.3. PESTEL ANALYSIS
  • 9.4. SUPPLY CHAIN ANALYSIS
  • 9.5. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. THE UNITED KINGDOM
    • 10.2.2. GERMANY
    • 10.2.3. FRANCE
    • 10.2.4. ITALY
    • 10.2.5. SPAIN
    • 10.2.6. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. JAPAN
    • 10.3.2. CHINA
    • 10.3.3. INDIA
    • 10.3.4. AUSTRALIA
    • 10.3.5. SOUTH KOREA
    • 10.3.6. REST OF ASIA PACIFIC
  • 10.4. REST OF WORLD
    • 10.4.1. LATIN AMERICA
    • 10.4.2. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET POSITION ANALYSIS
  • 11.2. COMPANY PROFILES
    • 11.2.1. ABBVIE, INC.
    • 11.2.2. ALBEMARLE CORPORATION
    • 11.2.3. AUROBINDO PHARMA
    • 11.2.4. BAYER AG
    • 11.2.5. BOEHRINGER INGELHEIM GMBH
    • 11.2.6. BRISTOL-MYERS SQUIBB
    • 11.2.7. CIPLA
    • 11.2.8. DR. REDDY'S LABORATORIES
    • 11.2.9. ELI LILLY AND COMPANY
    • 11.2.10. LONZA GROUP AG
    • 11.2.11. MERCK & CO., INC.
    • 11.2.12. MYLAN N.V.
    • 11.2.13. NOVARTIS
    • 11.2.14. SUN PHARMACEUTICALS INDUSTRIES, LTD.
    • 11.2.15. TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 3 GLOBAL GENERIC APIS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL INNOVATIVE APIS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL CAPTIVE APIS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL MERCHANT APIS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL BIOTECH MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL MONOCLONAL ANTIBODIES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL RECOMBINANT PROTEINS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL VACCINES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL SYNTHETIC MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL CARDIOVASCULAR DISEASE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL ONCOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL CNS AND NEUROLOGICAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL ORTHOPEDIC DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 20 GLOBAL ENDOCRINOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 21 GLOBAL PULMONOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 22 GLOBAL GASTROINTESTINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 23 GLOBAL NEPHROLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 24 GLOBAL OPHTHALMOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 25 GLOBAL OTHER APPLICATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 26 SALES ANALYSIS OF ALL THE MOLECULES 2014-2017 ($ MILLION)
  • TABLE 27 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 28 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 29 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 30 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 31 REST OF WORLD ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 32 ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

LIST OF FIGURES

  • FIGURE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL POPULATION BY AGE GROUP
  • FIGURE 3 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
  • FIGURE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
  • FIGURE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
  • FIGURE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 16 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
  • FIGURE 21 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
  • FIGURE 24 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
  • FIGURE 25 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
  • FIGURE 26 PORTER'S FIVE FORCE MODEL
  • FIGURE 27 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 28 THE UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 THE UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 34 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 35 REST OF EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 36 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 37 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 39 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 40 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 41 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 42 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 43 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
Back to Top